Arbutus Biopharma Corporation (ABUS)

Etorro trading 970x250
Arbutus Biopharma Corporation (ABUS) Logo

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974

Arbutus Biopharma Corporation News and around…

Latest news about Arbutus Biopharma Corporation (ABUS) common stock and company :

Analysts Just Shipped A Dazzling Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Estimates
10 Aug, 2022 Yahoo! Finance

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript
04 Aug, 2022 FinancialContent

ABUS earnings call for the period ending June 30, 2022.

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
04 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca/Merck's ...

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2022 Yahoo! Finance

Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Recap: Arbutus Biopharma Q2 Earnings
04 Aug, 2022 FinancialContent

Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what ...

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
04 Aug, 2022 Yahoo! Finance

Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
21 Jul, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Verve Therapeutics, Vertex ...

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
21 Jul, 2022 Yahoo! Finance

WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference call/webcast are as follows: •Q2/2022 Press Release:Thursday, August

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor
20 Jul, 2022 Yahoo! Finance

Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that while its partner, Assembly Biosciences

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
06 Jul, 2022 Yahoo! Finance

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
28 Jun, 2022 FinancialContent

JMP Securitiesreiterates its Market Outperform rating but reduces theprice target to $9 from $10onArbutus ...

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
25 Jun, 2022 Yahoo! Finance

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after meeting stopping criteria, there has been no evidence of virologic or clinical relapse in 8-24 weeks of follow-up Preliminary data to date have shown that AB-729 remains generally safe and well-tolerated

Look Under The Hood: VTWO Has 46% Upside
15 Jun, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $99.99 per unit.

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
08 Jun, 2022 Yahoo! Finance

Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that seven abstracts have been accepted for poster presentations at the European Association for the Study of the

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
06 Jun, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
06 Jun, 2022 Yahoo! Finance

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapyWARMINSTER, Pa. and OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and develop

Arbutus to Participate in June Investor Conferences
02 Jun, 2022 Yahoo! Finance

WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York: Jefferies Healthcare Conference (June 8 - 10, 2022) Fireside Chat: 3:00 pm ET on Thursday, June 9, 2022Presenters: Michael McE

Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
26 May, 2022 Yahoo! Finance

WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of Arbutus’ oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual

Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds
20 May, 2022 Yahoo! Finance

The Pennsylvania Biotechnology Center of Bucks County and its affiliated organizations have generated an economic impact of $7.3 billion for the state during the past six years, according to a new study. The analysis, conducted by KLIOS Consulting economist Richard M. Stein, found that between the beginning of 2016 and the end of 2021, the biotech center produced a $2.3 billion direct impact tied to spending and economic activity at the center, and another $3.5 billion in indirect spending elsewhere in Pennsylvania tied to initial economic activity at the center. The remaining $1.5 billion represents the center's "induced impact," which is economic benefit related to additional household spending created from biotech center activities and related indirect economic activity.

Arbutus to Present at H.C. Wainwright Global Investment Conference
17 May, 2022 Yahoo! Finance

WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL. A live webcast of the presentation can be ac

Morning Brief: Top Financial Stories Dominating on Monday, May 9
09 May, 2022 FinancialContent

CNBC Ford Motor Selling 8M Shares Of Rivian Automotive Ford Motor Company(NYSE:F) will sell 8 millionRivian ...

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
09 May, 2022 FinancialContent

Moderna Inc(NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 ...

Party Time: Brokers Just Made Major Increases To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Earnings Forecasts
07 May, 2022 Yahoo! Finance

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Arbutus Biopharma (ABUS) Q1 2022 Earnings Call Transcript
05 May, 2022 FinancialContent

ABUS earnings call for the period ending March 31, 2022.

Arbutus Biopharma: Q1 Earnings Insights
05 May, 2022 FinancialContent

Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what ...

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
05 May, 2022 Yahoo! Finance

Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
05 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For ...

Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
28 Apr, 2022 FinancialContent

Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings ...

First Week of December 16th Options Trading For Arbutus Biopharma (ABUS)
20 Apr, 2022 FinancialContent

Investors in Arbutus Biopharma Corp (ABUS) saw new options become available this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
18 Mar, 2022 FinancialContent

Canada-basedAcuitas Therapeutics Inchas suedArbutus Biopharma Corporation(NASDAQ: ABUS) in Manhattan federal ...

Arbutus Biopharma Corporation (ABUS) is a NASDAQ Common Stock listed in , ,

970x250